Central Nervous System (Psychiatric) Clinical Trials
A Multicenter, Long-Term, Open-Label Study to Assess the Safety and Tolerability of Aripiprazole as Adjunctive Therapy in the Treatment of Outpatients with Major Depressive Disorder. (Bristol-Myers Squibb)
Evaluation of 24 Hour Motor Activity of Buproprion XL vs Placebo in Patients with Major Depressive Disorder. (Glaxo Wellcome and Campbell University)
A Multi-Center, Double-blind, Randomized-withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilization Period. (AstraZeneca)
A Multicenter, Double-blind, Study on the Efficacy and Safety of Aripiprazole in Combination with Lamotrigine in the Long-term maintenance Treatment of Patients with Bipolar I Disorder with a Recent Manic or Mixed Episode. (Bristol-Myers Squibb)
An 8-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-controlled (Escitalopram Oxalate 10mg) Study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel) 150 mg/day and 300 mg/day Compared with Placebo in the Treatment of Generalized Anxiety Disorder. (AstraZeneca)
A 6-week Multicenter, Double-Blind, Randomized, Parallel-group, Placebo-controlled and Active-controlled (Duloxetine 60 mg/day) Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) 150 mg/day and 300 mg/day as monotherapy in the Treatment of Patients with Major Depressive Disorder. (AstraZeneca)
Bradlyn, AS (Investigator). A Multicenter, Randomized, 8-week Double-Blind Acute Phase Followed by a 6-month Continuation Phase (Open-Label or Double-Blind) Study to Evaluate the Efficacy, Safety, and Tolerability of DVS SR Versus Escitalopram in Postmenopausal Women with Major Depressive Disorder. (Wyeth Research) |